**Ocular Melanoma**

**Metastatic**
- Any Line
  - **MEL0034**
    - Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Hepatic Dominant Ocular Melanoma
    - PI: Reddy
    - Sponsor: Delcath Systems, Inc.
  - **SKIN0055**
    - Phase II/III SD-101 a TLR9 Agonist +/- Intravenous Checkpoint Blockade in Metastatic Uveal Melanoma
    - PI: Reddy
    - Sponsor: TriSalus Life Sciences

**Small primary**
- **MEL0037**
  - Phase III Randomized Masked Controlled Trial to Evaluate Efficacy & Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Primary Indeterminate Lesions or Small Choroidal Melanoma
  - PI: Murthyunjaya
  - Sponsor: Aura Biosciences, Inc.
- **MEL0039**
  - A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)
  - PI: Murthyunjaya
  - Sponsor: Jaeb Center for Health Research

**Adjuvant / Neoadjuvant**
- **MEL0040**
  - Phase II (Neo)Adjuvant IDE196 (Darovasertib) in Patients with Localized Ocular Melanoma
  - PI: Funchain
  - Sponsor: IDEAYA Biosciences